A generic drug industry association head says concessions in free trade pacts have been 'death by a thousand cuts' for the industry.
U.S President Donald J. Trump, middle, with then-Mexican President Enrique Pena Nieto, left, and Canadian Prime Minister Justin Trudeau, right, at the USMCA signing ceremony on Nov. 30, 2018, in Buenos Aires, Argentina. The renegotiated trade pact increases protection on biologics from eight to 10 years. Photo by Shealah Craighead/White House
Increased protection of innovative drugs will lead to an added cost for Canadians, but the trade concession doesn’t infringe on Canada’s ability to implement a national pharmacare plan, says an industry expert.
People. Policy. Politics. This is an exclusive subscriber-only story.
Fostering use of Inuit languages was a key aim in creating Nunavut, but 20 years later, NTI president Aluki Kotierk says there's been a 'failure' when it comes to providing essential services to the public in Inuktut.